Merus N.V., a biotechnology firm specializing in oncology, has announced a proposed underwritten public offering of its common shares. All shares in this offering will be provided by Merus, with an additional option for underwriters to purchase up to 15% more shares. The company plans to use the proceeds to further the clinical development of its product candidates and for general corporate purposes. The offering, managed by Jefferies, BofA Securities, Leerink Partners, and others, is contingent on market and closing conditions. A preliminary prospectus supplement will be available on the SEC's website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.